<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H7EB686131FB84B9BA8B1A35E6466C953" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 1864 IH: Risky Research Review Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-03-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1864</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250305">March 5, 2025</action-date><action-desc><sponsor name-id="G000568">Mr. Griffith</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HSY00">Committee on Science, Space, and Technology</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title 31, United States Code, to establish the Life Sciences Research Security Board, and for other purposes.</official-title></form><legis-body id="HD0E750FCAB954E7794A171A126765172" style="OLC"><section section-type="section-one" id="HAFABAFE375C949F79464E2237AD98D60" changed="not-changed"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Risky Research Review Act</short-title></quote>.</text></section><section commented="no" display-inline="no-display-inline" id="HAD8B3BC411134BACA46DDD904407BDDD" changed="not-changed"><enum>2.</enum><header>Life Sciences Research Security Board</header><subsection commented="no" display-inline="no-display-inline" id="HC0D0A1F0A20A45D4AE7596D3889D983A" changed="not-changed"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Subtitle V of title 31, United States Code, is amended by adding at the end the following:</text><quoted-block style="USC" display-inline="no-display-inline" id="HFABCEBB342014E809FD0B385CAD6CCB5" changed="not-changed"><chapter id="H05C0086801B24546BC1C79620C7AC7DB" style="OLC" changed="not-changed"><enum>79</enum><header>Life Sciences Research Security Board</header><toc changed="not-changed"><toc-entry level="section" changed="not-changed">7901. Definitions. </toc-entry><toc-entry level="section" changed="not-changed">7902. Establishment and membership. </toc-entry><toc-entry level="section" changed="not-changed">7903. Board personnel. </toc-entry><toc-entry level="section" changed="not-changed">7904. Board mission and functions. </toc-entry><toc-entry level="section" changed="not-changed">7905. Agency procedures; referral to Board. </toc-entry><toc-entry level="section" changed="not-changed">7906. Board review. </toc-entry><toc-entry level="section" idref="H0773999330DD4FE885DF581E00ECF7F6" changed="not-changed">7907. GAO Audits. </toc-entry><toc-entry level="section" changed="not-changed">7908. Funding. </toc-entry></toc><section id="H0B98F58FB90E45E89178EE7A311AB76E" changed="not-changed"><enum>7901.</enum><header>Definitions</header><text display-inline="no-display-inline">In this chapter:</text><paragraph commented="no" display-inline="no-display-inline" id="H7AF74644206B44448B0925D5A9602F18" changed="not-changed"><enum>(1)</enum><header>Agency</header><text display-inline="yes-display-inline">The term <term>agency</term> has the meaning given the term in section 552(f) of title 5. </text></paragraph><paragraph id="HAEE88A8EEB92468289066CBE66878D70" changed="not-changed"><enum>(2)</enum><header>Appropriate congressional committees</header><text>The term <term>appropriate congressional committees</term> means the Committee on Homeland Security and Governmental Affairs of the Senate and the Committee on Energy and Commerce of the House of Representatives.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H74351323454C4D9CB6F3FC428DC2A2A9" changed="not-changed"><enum>(3)</enum><header>Board</header><text display-inline="yes-display-inline">The term <term>Board</term> means the Life Sciences Research Security Board established under section 7902(a).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H8311471CB1854C60BE5E283A33A14112" changed="not-changed"><enum>(4)</enum><header>Dual use research of concern</header><text>The term <term>dual use research of concern</term>—</text><subparagraph commented="no" display-inline="no-display-inline" id="HF5155AB2B8024D63A3F19720C8B59929" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">means life sciences research that, based on current understanding, can be reasonably anticipated to provide knowledge, information, products, or technologies that could—</text><clause commented="no" display-inline="no-display-inline" id="HFE53BDA948A541558B258EFF1327A22A" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">be misapplied to do harm with no modification or only a minor modification; and</text></clause><clause commented="no" display-inline="no-display-inline" id="HD6BA0B2E9F504C8BBAA9590209B35970" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">pose a significant threat with potential consequences to public health and safety, agricultural crops and other plants, animals, materiel, or national security; and</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HF93042E13E954EC3A991E3EE80428DD5" changed="not-changed"><enum>(B)</enum><text>includes—</text><clause commented="no" display-inline="no-display-inline" id="H8193031BD65A42DA8D3F77C1E0678EC3" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">life sciences research that could—</text><subclause commented="no" display-inline="no-display-inline" id="HCDAD75137D884FAAA3AF2CB2B7155962" changed="not-changed"><enum>(I)</enum><text>increase transmissibility of a pathogen within or between host species;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HFF2A5DCDF939491E8EEC3FCB376B1839" changed="not-changed"><enum>(II)</enum><text display-inline="yes-display-inline">increase the virulence of a pathogen or convey virulence to a non-pathogen;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HA1B13BB699AE4565BFD9A751ED1997D3" changed="not-changed"><enum>(III)</enum><text display-inline="yes-display-inline">increase the toxicity of a known toxin or produce a novel toxin;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HA5016804F5AF4F5394E3F83F3A4B8A8C" changed="not-changed"><enum>(IV)</enum><text display-inline="yes-display-inline">increase—</text><item commented="no" display-inline="no-display-inline" id="H8F1E626D3D214102A4B1F1A194FA68E1" changed="not-changed"><enum>(aa)</enum><text display-inline="yes-display-inline">the stability of a pathogen or toxin in the environment; or</text></item><item commented="no" display-inline="no-display-inline" id="HF05150C4F276400AAC2FE056B05F2DC4" changed="not-changed"><enum>(bb)</enum><text display-inline="yes-display-inline">the ability to disseminate a pathogen or toxin;</text></item></subclause><subclause commented="no" display-inline="no-display-inline" id="H7AE012E9DC6B4F7AADB68A71CB845367" changed="not-changed"><enum>(V)</enum><text display-inline="yes-display-inline">alter the host range or tropism of a pathogen or toxin;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H476ECC12725E45FA93D3DAB081208EDF" changed="not-changed"><enum>(VI)</enum><text display-inline="yes-display-inline">decrease the ability for a human or veterinary pathogen or toxin to be detected using standard diagnostic or analytical methods;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HA5D42D94C265442281A44A862010773E" changed="not-changed"><enum>(VII)</enum><text display-inline="yes-display-inline">increase resistance of a pathogen or toxin to clinical or veterinary prophylactic or therapeutic interventions;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H307981865AD24F0289C4CE8C08CD1DCE" changed="not-changed"><enum>(VIII)</enum><text display-inline="yes-display-inline">alter a human or veterinary pathogen or toxin to disrupt the effectiveness of pre-existing immunity, via immunization or natural infection, against the pathogen or toxin;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HBF0FACE4322E4CC6879DDC82FDB98E36" changed="not-changed"><enum>(IX)</enum><text display-inline="yes-display-inline">enhance the susceptibility of a host population to a pathogen or toxin;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H0B62DF435A074AE1B1B1B0B90420F805" changed="not-changed"><enum>(X)</enum><text display-inline="yes-display-inline">enhance transmissibility of a pathogen in humans;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HC2C7536589D343F6951543277879C3C2" changed="not-changed"><enum>(XI)</enum><text display-inline="yes-display-inline">enhance the virulence of a pathogen in humans;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H394EF2012E26450AB7CD855408686432" changed="not-changed"><enum>(XII)</enum><text display-inline="yes-display-inline">enhance the immune evasion of a pathogen in humans, such as by modifying the pathogen to disrupt the effectiveness of pre-existing immunity via immunization or natural infection; or</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HD35AFB23BFF44775ACE892B0ECE6182C" changed="not-changed"><enum>(XIII)</enum><text display-inline="yes-display-inline">generate, use, reconstitute, or transfer an eradicated or extinct high-consequence pathogen; and</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="HF5002B12A1CB4DAE96F303A93BDFE117" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">any other category of life sciences research that the Board, by majority vote of the members of the Board, identifies and publishes in the Federal Register. </text></clause></subparagraph></paragraph><paragraph id="HC331AE29BB2643C780642A62215401F3" changed="not-changed"><enum>(5)</enum><header>Employee</header><text>The term <term>employee</term> means an individual described in section 2105(a) of title 5.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H7E218497090544A88A6E6A7D2576CDEA" changed="not-changed"><enum>(6)</enum><header>Federal funding</header><text display-inline="yes-display-inline">The term <term>Federal funding</term> means amounts awarded by an agency pursuant to an intramural or extramural grant, cooperative agreement, interagency agreement, contract, or other instrument.</text></paragraph><paragraph id="H33810104F4044698BD061162E33ABE84" changed="not-changed"><enum>(7)</enum><header>Gain of function research</header><text>The term <term>gain of function research</term> means a research experiment that may enhance the transmissibility or virulence of a high-consequence pathogen.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H22A01FC9CA6D47279912BD160D454395" changed="not-changed"><enum>(8)</enum><header>High-consequence pathogen</header><text display-inline="yes-display-inline">The term <term>high-consequence pathogen</term>—</text><subparagraph commented="no" display-inline="no-display-inline" id="HB252A623C1DB407993E2DDC2BF3ECFFB" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">means a wild-type or synthetic pathogen that—</text><clause commented="no" display-inline="no-display-inline" id="H02AD24C9800C4BA3935076346393B6CB" changed="not-changed"><enum>(i)</enum><subclause commented="no" display-inline="yes-display-inline" id="H86A8A302B7DD4C6DB9C6799CBE9C638A" changed="not-changed"><enum>(I)</enum><text display-inline="yes-display-inline">is likely capable of wide and uncontrollable spread in human populations; and</text></subclause><subclause commented="no" display-inline="no-display-inline" indent="up1" id="HA6D99651AD524EEEBB053AD4B15F9254" changed="not-changed"><enum>(II)</enum><text display-inline="yes-display-inline">would likely cause moderate to severe disease or mortality in humans; or</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="HBDDE6401BC4144FEB7D71CDB4C4FB2A8" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">is—</text><subclause commented="no" display-inline="no-display-inline" id="HC5549B58976A4B369AFFBC2E9582814D" changed="not-changed"><enum>(I)</enum><text display-inline="yes-display-inline">subject to subparagraph (B), influenza A virus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HD15EF684E1A04A1FB0C401649895C58D" changed="not-changed"><enum>(II)</enum><text display-inline="yes-display-inline">classified under subgenus Sarbecovirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HD112BE913CFD4A539695AE759AEB11BB" changed="not-changed"><enum>(III)</enum><text display-inline="yes-display-inline">classified under subgenus Merbecovirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H5E7B26F6E4AF408EB7B63F25E9BDB837" changed="not-changed"><enum>(IV)</enum><text display-inline="yes-display-inline">Variola orthopoxvirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H69C9A8FC89B54C44967F8AF1A8A1B2F4" changed="not-changed"><enum>(V)</enum><text display-inline="yes-display-inline">Mpox orthopoxvirus; </text></subclause><subclause commented="no" display-inline="no-display-inline" id="H68F235356C524DC39A911104F7ABB592" changed="not-changed"><enum>(VI)</enum><text display-inline="yes-display-inline">Nipah henipavirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H3AD8F2F5982744E58D005307B10DB9EF" changed="not-changed"><enum>(VII)</enum><text display-inline="yes-display-inline">Hendra henipavirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H91CA5D5C0BD647F9B9FFA35952FB86FF" changed="not-changed"><enum>(VIII)</enum><text display-inline="yes-display-inline">Ebola orthoebolavirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HD7002051B7114A13B4B3074A009066A1" changed="not-changed"><enum>(IX)</enum><text display-inline="yes-display-inline">Marburg marburgvirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H8F9F40153BD44820B8F4CC5C8667DAC9" changed="not-changed"><enum>(X)</enum><text display-inline="yes-display-inline">Lassa mammarenavirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H33B6AD6366614E85A1276C84FAB88652" changed="not-changed"><enum>(XI)</enum><text display-inline="yes-display-inline">Junin arenavirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H49D30BE929FA4FC29852389AB0D332D4" changed="not-changed"><enum>(XII)</enum><text display-inline="yes-display-inline">Crimean-Congo hemorrhagic fever orthonairovirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H5F479FA5CB634E54BE7E2D6245B77A2D" changed="not-changed"><enum>(XIII)</enum><text display-inline="yes-display-inline">Hantaan orthohantavirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H66BD3B0ED71943DA8F57896E49BF8E04" changed="not-changed"><enum>(XIV)</enum><text display-inline="yes-display-inline">Sin Nombre orthohantavirus;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H26DBB8ED10334FEFAFC41529E84C165B" changed="not-changed"><enum>(XV)</enum><text display-inline="yes-display-inline">Yersinia pestis;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HDB846BB8C061474BAF6E5E2A6A0EEAAC" changed="not-changed"><enum>(XVI)</enum><text display-inline="yes-display-inline">a select agent or toxin, work with which poses a significant risk of deliberate misuse;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H50B46DEF20BE439497BDA0B4F699E3C4" changed="not-changed"><enum>(XVII)</enum><text display-inline="yes-display-inline">any other pathogen or category of pathogen that a majority of members of the Board—</text><item commented="no" display-inline="no-display-inline" id="H9A39CC508C4E43ADA0A29AFF658F9FC5" changed="not-changed"><enum>(aa)</enum><text display-inline="yes-display-inline">identifies as a high-consequence pathogen; and</text></item><item commented="no" display-inline="no-display-inline" id="H666F854E2DBC4B1C9C539F62C235A102" changed="not-changed"><enum>(bb)</enum><text display-inline="yes-display-inline">publishes in the Federal Register; or</text></item></subclause><subclause commented="no" display-inline="no-display-inline" id="H1844778030C64530A13A61DBB05337DC" changed="not-changed"><enum>(XVIII)</enum><text>any synthetic construct of a pathogen or category of pathogen described in this clause; and</text></subclause></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HE55447281C2B42B59CF8EDAC9F6091D0" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">does not include a seasonal influenza virus, unless a seasonal influenza virus has been manipulated to include genetic sequences from a pathogen described in subparagraph (A). </text></subparagraph></paragraph><paragraph id="H527F8CE68F7B454AADA230CBCBCEFA44" changed="not-changed"><enum>(9)</enum><header>High-risk life sciences research</header><text>The term <term>high-risk life sciences research</term> means life sciences research that is—</text><subparagraph commented="no" display-inline="no-display-inline" id="HEF5DDF99A0364604B3E0DAF1A5695764" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">dual use research of concern involving a high-consequence pathogen; or</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H4DE7CC53F1E94D1EAA9C76B334AAADEE" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">gain of function research.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H67F9BF82FE574D74901F0C9113F5DC12" changed="not-changed"><enum>(10)</enum><header>Life sciences research</header><text display-inline="yes-display-inline">The term <term>life sciences research</term>—</text><subparagraph commented="no" display-inline="no-display-inline" id="HFC52181A9189411D8C2667A7546F71B7" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">means the study or use of a living organism, a virus, or a product of a living organism or virus; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HCC5B1AE8ECA041F099FFCA0E9010B386" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">includes each discipline, methodology, and application of biology, including biotechnology, genomics, proteomics, bioinformatics, and pharmaceutical and biomedical research and techniques.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H371D4DBE52CC482D99389B8B27D8DAB4" changed="not-changed"><enum>(11)</enum><header>Select agent or toxin</header><text>The term <term>select agent or toxin</term> means a select agent or toxin identified under—</text><subparagraph commented="no" display-inline="no-display-inline" id="H4770B94E187240B6B4CC4AF7BEEA5DDE" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">section 73.3(b) of title 42, Code of Federal Regulations, as in effect on the date of enactment of the <short-title>Risky Research Review Act</short-title>;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HD7B63394287C4C5599D8098FA3DAA758" changed="not-changed"><enum>(B)</enum><text>section 331.3(b) of title 7, Code of Federal Regulations, as in effect on the date of enactment of the <short-title>Risky Research Review Act</short-title>; or</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HECCFA96E8762499B9B9A9CA215BCC930" changed="not-changed"><enum>(C)</enum><text>section 121.3(b) of title 9, Code of Federal Regulations, as in effect on the date of enactment of the <short-title>Risky Research Review Act</short-title>.</text></subparagraph></paragraph></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="HF2D514C954504A57881C7FB830353667" changed="not-changed"><enum>7902.</enum><header display-inline="yes-display-inline">Establishment and membership</header><subsection commented="no" display-inline="no-display-inline" id="H45C738BA58644901B5A95C8959F76912" changed="not-changed"><enum>(a)</enum><header>Establishment</header><text>There is established as an independent agency within the Executive Branch a board to be known as the <quote>Life Sciences Research Security Board</quote> to review proposed Federal funding for life sciences research in accordance with section 7906.</text></subsection><subsection id="HF86F1E90C0314643881131637A93ACFF" changed="not-changed"><enum>(b)</enum><header>Appointment of members</header><paragraph commented="no" display-inline="no-display-inline" id="H737746ED4B16426DBFFF3A12C7C92C47" changed="not-changed"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The President shall appoint, without regard to political affiliation, 9 individuals who are citizens of the United States to serve as members of the Board for not more than 2 terms of 4 years each, including—</text><subparagraph commented="no" display-inline="no-display-inline" id="H6161DF9060D64BBC86A10753385E4644" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">the Executive Director appointed under section 7903(a);</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H97CB4952C9AE4CF3AD47F251E4430796" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">5 nongovernmental scientists in a life sciences field;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H957AC234A008485294BCB8F13DDA5A42" changed="not-changed"><enum>(C)</enum><text display-inline="yes-display-inline">2 nongovernmental national security experts; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H39F82540B61A47FD91737FE61388A1DF" changed="not-changed"><enum>(D)</enum><text>1 nongovernmental biosafety expert.</text></subparagraph></paragraph><paragraph id="H5BA92E9976224DA6BC4EA3FD9DC43214" changed="not-changed"><enum>(2)</enum><header>Period for nominations</header><text>The President shall make appointments, other than the Executive Director, to the Board not later than 30 days after the date of enactment of this chapter.</text></paragraph><paragraph id="H813ACBB6B7754A14B380B700DB7108E3" changed="not-changed"><enum>(3)</enum><header>Considerations of recommendations</header><text>The President shall make appointments to the Board after considering individuals recommended by the chair and ranking member of the appropriate congressional committees.</text></paragraph><paragraph id="H4CA8E7F02EA54BC88EF044794B945F74" changed="not-changed"><enum>(4)</enum><header>Qualifications</header><text>Individuals appointed to the Board—</text><subparagraph commented="no" display-inline="no-display-inline" id="H0D058CC9DE60463EAAA591FC747EFD48" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">shall—</text><clause id="H0C79C8C5D830448B90CD3857B1CD9DA1" changed="not-changed"><enum>(i)</enum><text>be impartial individuals; and</text></clause><clause id="H9EDA35FC10B34A32B22156E11C9267E3" changed="not-changed"><enum>(ii)</enum><text>be distinguished individuals of high national professional reputation in their respective fields who are capable of exercising the independent and objective judgment necessary to conduct an impartial assessment of the potential risks and benefits associated with Federal funding of high-risk life sciences research to public health and national security; and</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H048351A64741450F991B2D2D9E591339" changed="not-changed"><enum>(B)</enum><text>may not be an employee on the date of the appointment or during the 3-year period preceding the date of the appointment.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H7592EDCD58A54D3AA7F8101DCCAF6787" changed="not-changed"><enum>(5)</enum><header>Limitations</header><text>Not more than 4 concurrent members of the Board may be an employee, a subcontractor, a previous employee, or a previous subcontractor of—</text><subparagraph commented="no" display-inline="no-display-inline" id="H893103E8A9794F83B699AF1D77669602" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">the Department of Defense;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H275AF0AC0BC8408E92DE4B46B3D7833F" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">the Department of Homeland Security;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HA0CBC98B644646E8B7DEFF90BB4D08C1" changed="not-changed"><enum>(C)</enum><text display-inline="yes-display-inline">the National Institute of Allergy and Infectious Diseases of the Department of Health and Human Services;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H49A4C0BAD0A54D5F9BD1F87EA257DE0E" changed="not-changed"><enum>(D)</enum><text>the Office of the Director of National Intelligence; or</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HFC2C0BDD00E8473F9AA3284EB34B1AD3" changed="not-changed"><enum>(E)</enum><text>the Department of Energy.</text></subparagraph></paragraph><paragraph id="H36F79B4C6C7C44F7810F8832B0030DEC" changed="not-changed"><enum>(6)</enum><header>Consideration by the Senate</header><subparagraph commented="no" display-inline="no-display-inline" id="H2368DC569FB04BAAB61CE5087E63287B" changed="not-changed"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Nominations for appointment to the position of Executive Director of the Board shall be referred to the Committee on Homeland Security and Governmental Affairs of the Senate for consideration.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H1169474E51D24C8390EEEBE1A3180700" changed="not-changed"><enum>(B)</enum><header>Renomination</header><text display-inline="yes-display-inline">A member of the Board who is recommended to serve a second term shall be nominated for appointment to the Board, and such nomination shall be referred pursuant to subparagraph (A).</text></subparagraph></paragraph><paragraph id="H896A2D75DC014FE2A95D0CAC24077FE9" changed="not-changed"><enum>(7)</enum><header>Vacancy</header><text>Not later than 30 days after the date on which a vacancy on the Board occurs, the vacancy shall be filled in the same manner as specified for the original appointment.</text></paragraph><paragraph id="H79A91C678FA54E6FAEECBAA2296984FE" changed="not-changed"><enum>(8)</enum><header>Removal</header><subparagraph commented="no" display-inline="no-display-inline" id="H48958C76F38E4E9390DA64C7C36FD490" changed="not-changed"><enum>(A)</enum><header display-inline="yes-display-inline">In general</header><text>No member of the Board shall be removed from office, other than by—</text><clause commented="no" display-inline="no-display-inline" id="H218E499D3E894081B53AF2C80AFBCAD4" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">impeachment and conviction;</text></clause><clause id="HD8C16A60046D42C1A0D1FE2408EF7474" changed="not-changed"><enum>(ii)</enum><text>the action of the President for inefficiency, neglect of duty, malfeasance in office, physical disability, mental incapacity, or any other condition that substantially impairs the performance of the member’s duties; or</text></clause><clause id="H8D0CC078DB83453C85EFE1A3393ECD15" changed="not-changed"><enum>(iii)</enum><text>the Board in accordance with subparagraph (B).</text></clause></subparagraph><subparagraph id="HC00D6D95959242EEA5B43A41AFD160D7" changed="not-changed"><enum>(B)</enum><header>Action by Board</header><text>If the Director of the Office of Government Ethics determines that participation by a member of the Board in high-risk life sciences research constitutes a conflict of interest, the Board shall take steps to mitigate or manage the conflict, which may include removal.</text></subparagraph><subparagraph id="HA62BEF3B7CA64D1990E8CCD0C2852E2A" changed="not-changed"><enum>(C)</enum><header>Notice of removal by President</header><clause commented="no" display-inline="no-display-inline" id="HE5197F5E1E8E429DA7AC249308D2D301" changed="not-changed"><enum>(i)</enum><header display-inline="yes-display-inline">In general</header><text>In the case of the removal of a member of the Board by the President as described in subparagraph (A)(ii), not later than 10 days after the removal, the President shall submit to the chair and ranking member of the appropriate congressional committees a report specifying the facts found and the grounds for removal.</text></clause><clause id="HF2EC9B5913364482B8BF5CABBA600AFE" changed="not-changed"><enum>(ii)</enum><header>Publication of report</header><text>The President shall publish in the Federal Register each report submitted under clause (i), except that the President may, if necessary to protect the rights of a person named in the report or to prevent undue interference with any pending prosecution, postpone or refrain from publicly publishing any or all of the report until the completion of such pending cases or pursuant to privacy protection requirements in law.</text></clause></subparagraph></paragraph></subsection><subsection id="H03386593866949D9818794A517757C72" changed="not-changed"><enum>(c)</enum><header>Mandatory conflicts of interest review</header><paragraph id="HB3271AAD61504EB3ACDA26CB9369739C" changed="not-changed"><enum>(1)</enum><header>In general</header><text>The Board, in consultation with the Director of the Office of Government Ethics, shall—</text><subparagraph id="H31BD5A61305246E295958F649BE4C6CE" changed="not-changed"><enum>(A)</enum><text>not later than 180 days after the date of the enactment of this chapter—</text><clause id="H50438AB09495475AB46533663179A3FC" changed="not-changed"><enum>(i)</enum><text>establish criteria to determine whether there is a conflict of interest with respect to any individual appointed to the Board, taking into consideration requirements under Federal law relating to ethics requirements for employees; and</text></clause><clause id="H022D37FF980243A08C4FFC6CD584EC26" changed="not-changed"><enum>(ii)</enum><text>upon an appointment of a member to the Board under subsection (a)(1) thereafter, conduct a review of each individual nominated and appointed to the Board to ensure the individual does not have any conflict of interest under the criteria established pursuant to clause (i); and</text></clause></subparagraph><subparagraph id="HEF24B512C07F43368D3595BC3B0BC0E2" changed="not-changed"><enum>(B)</enum><text>periodically thereafter, conduct a review of each individual nominated and appointed to the Board to ensure the individual does not have any conflict of interest under the criteria established pursuant to subparagraph (A)(i) during the term of service of the individual.</text></subparagraph></paragraph><paragraph id="HE68C4CC8202A41258330C14C17C7A5C6" changed="not-changed"><enum>(2)</enum><header>Notification</header><subparagraph id="HF5BEDB5F4DD44BF183D508FF0E0AD544" changed="not-changed"><enum>(A)</enum><header>In general</header><text>Not later than 3 days after the date on which the Director of the Office of Government Ethics becomes aware that a member of the Board possesses a potential conflict of interest under the criteria established pursuant to paragraph (1)(A)(i), the Director of the Office of Government Ethics shall notify the chair and ranking member of the appropriate congressional committees of the potential conflict of interest.</text></subparagraph><subparagraph id="HF24C3066B75B40CB9288421177F4A1DF" changed="not-changed"><enum>(B)</enum><header>Notification by member</header><text>Not later than 30 days after the date on which a member of the Board becomes aware that another member of the Board possesses a potential conflict of interest under the criteria established pursuant to paragraph (1)(A)(i), the member of the Board or the Executive Director of the Board shall notify the chair and ranking member of the appropriate congressional committees of the potential conflict of interest.</text></subparagraph></paragraph></subsection><subsection id="H39628C504350435ABDEFD28C89B0323C" changed="not-changed"><enum>(d)</enum><header>Security clearances</header><text display-inline="yes-display-inline">All members of the Board shall be granted all the necessary security clearances and accesses, including to relevant Presidential and department or agency special access and compartmented access programs, in an accelerated manner, subject to the standard procedures for granting such clearances. All nominees for appointment to the Board shall qualify for the necessary security clearances and accesses prior to being considered for confirmation by the Committee on Homeland Security and Governmental Affairs of the Senate.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="H042CAFF4908F48E7B9E422F833CFE573" changed="not-changed"><enum>(e)</enum><header>Participation in high-Risk life sciences research</header><paragraph commented="no" display-inline="no-display-inline" id="H412833F21AA24A8099410FE1B6977927" changed="not-changed"><enum>(1)</enum><header>Disclosure required</header><text display-inline="yes-display-inline">A member of the Board shall disclose whether the member has participated in or is currently participating in high-risk life sciences research.</text></paragraph><paragraph id="H81136920F9184DF78A1196A28CFB07D8" changed="not-changed"><enum>(2)</enum><header>Conflicts of interest</header><subparagraph id="H2E10E3CBD0DF4F10B26C803A5CE80F40" changed="not-changed"><enum>(A)</enum><header>In general</header><text>The participation in high-risk life sciences research by a member of the Board—</text><clause id="HDA5BB76B6E90493B9EFFB6193E1F4998" changed="not-changed"><enum>(i)</enum><text>shall be considered a potential conflict of interest; and</text></clause><clause id="H9F0B3A7E45FA41B0BF4F242EEDA83E17" changed="not-changed"><enum>(ii)</enum><text>shall be subject to scrutiny by the Director of the Office of Government Ethics.</text></clause></subparagraph><subparagraph id="HDC01CC4943E747A39F2D8047F1672CEE" changed="not-changed"><enum>(B)</enum><header>Determination</header><text>If the Director of the Office of Government Ethics determines that participation by a member of the Board in high-risk life sciences research constitutes a conflict of interest, the Board shall take steps to mitigate or manage the conflict, which may include—</text><clause id="HCF92AA1BF26344F3A64471F6080119F8" changed="not-changed"><enum>(i)</enum><text>the recusal of the affected member from relevant discussions and determinations; and</text></clause><clause id="H7EDDCDB7393F44209C754030F8A688CC" changed="not-changed"><enum>(ii)</enum><text>removal of the affected member from the Board. </text></clause></subparagraph></paragraph></subsection><subsection id="HA48C8FC3D51646D080C3E0F118A5F13B" changed="not-changed"><enum>(f)</enum><header>Compensation of members</header><paragraph commented="no" display-inline="no-display-inline" id="H406322799E70475B85362F879E145972" changed="not-changed"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to such rules as may be adopted by the Board, without regard to the provisions of chapter 51 and subchapter III of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/53">chapter 53</external-xref> of title 5 relating to classification and General Schedule pay rates, a member of the Board, other than the Executive Director, shall be compensated at a rate—</text><subparagraph commented="no" display-inline="no-display-inline" id="H67FA85A23DD94EA2B61606EA41D2F2A1" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">proposed by the Executive Director and approved by the Board;</text></subparagraph><subparagraph id="H7167FF8A380946658C4B1F5CECFF0AC3" changed="not-changed"><enum>(B)</enum><text>not to exceed the rate of basic pay for level II of the Executive Schedule; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H33EE56DFBFC44862850F5D22750B4F64" changed="not-changed"><enum>(C)</enum><text display-inline="yes-display-inline">that is commensurate with—</text><clause commented="no" display-inline="no-display-inline" id="HDCE43D58120D49F88AC450D56B500F81" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">the time a member of the Board spends engaged in the performance of duties on the Board; and</text></clause><clause commented="no" display-inline="no-display-inline" id="HEFA5E854312C49EC9CB260009D745E49" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">necessary traveling expenses.</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H789122AC978E4DB4AFD0569D7943408E" changed="not-changed"><enum>(2)</enum><header>Outside employment</header><text display-inline="yes-display-inline">Subject to terms and approval determined by the Director of the Office of Government Ethics, a member of the Board may maintain outside employment and affiliations while serving on the Board.</text></paragraph></subsection><subsection id="H36CA7AE74E86402B87EF99895A999E2F" changed="not-changed"><enum>(g)</enum><header>Oversight</header><paragraph id="HA07708F7E025414582AA45316490A867" changed="not-changed"><enum>(1)</enum><header>Senate</header><text>The Committee on Homeland Security and Governmental Affairs of the Senate shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="H3D37498EEF934FC89F9171A0D7A37A7F" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">have continuing legislative oversight jurisdiction in the Senate with respect to the official conduct of the Board and agency compliance with requirements issued by the Board; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HCB8A3F2DC0874187ABD8416FE688EFC6" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">have access to any records provided to or created by the Board.</text></subparagraph></paragraph><paragraph id="H9A8D6B633582402F9BFB99BB54A0194F" changed="not-changed"><enum>(2)</enum><header>House of Representatives</header><text>The Committee on Energy and Commerce of the House of Representatives shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="HD8A61199A1B64DC497DCEFAAB6F1B4D7" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">have continuing legislative oversight jurisdiction in the House of Representatives with respect to the official conduct of the Board and agency compliance with requirements issued by the Board; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H8EEC136A9BDF4F15A89FD29546A98D4D" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">have access to any records provided to or created by the Board.</text></subparagraph></paragraph><paragraph id="HE4327C82F7C74E719BFD0469AFCECA63" changed="not-changed"><enum>(3)</enum><header>Duty to cooperate</header><text>The Board shall have the duty to cooperate with the exercise of oversight jurisdiction described in this subsection.</text></paragraph><paragraph id="H90FE8ADA8EF94C9DA7E362C23535386C" changed="not-changed"><enum>(4)</enum><header>Security clearances</header><text>The chair and ranking member of the appropriate congressional committees, and designated committee staff, shall be granted all security clearances and accesses held by the Board, including to relevant Presidential and department or agency special access and compartmented access programs.</text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H214BB5BB72D94EF9A8022E7031833DEE" changed="not-changed"><enum>(h)</enum><header>Office space</header><paragraph commented="no" display-inline="no-display-inline" id="H4CB2434D8E2A49FEBD0C3868E57CD87D" changed="not-changed"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text>In selecting office space for the Board, the Board shall exhaust options for unused office spaces owned by the Federal Government as of the date of enactment of this chapter.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HA5A044EAC7EE43DA84ECBDA695315DCE" changed="not-changed"><enum>(2)</enum><header>Secure office space</header><subparagraph commented="no" display-inline="no-display-inline" id="HE83B768A108141BE997A9FC7A2E6D931" changed="not-changed"><enum>(A)</enum><header display-inline="yes-display-inline">Requests</header><text>In order to review or discuss classified information, the Board shall request an accommodation from relevant agencies to access sensitive compartmented information facilities on an as-needed basis.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H1DC74A02FF594220A638CBD04B32ABB7" changed="not-changed"><enum>(B)</enum><header>Fulfilment</header><text>The head of an agency from which the Board requests an accommodation under subparagraph (A) shall accommodate the request in a timely manner.</text></subparagraph></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="HA31C43539C534672A3DF1A3E3933216F" changed="not-changed"><enum>7903.</enum><header>Board personnel</header><subsection commented="no" display-inline="no-display-inline" id="H91DABAFD551E458BB2454B05F2687346" changed="not-changed"><enum>(a)</enum><header display-inline="yes-display-inline">Executive director</header><paragraph commented="no" display-inline="no-display-inline" id="HC51F0EA78D7D464C891C426F11C823CB" changed="not-changed"><enum>(1)</enum><header>Appointment</header><text display-inline="yes-display-inline">Not later than 45 days after the date of enactment of this chapter, the President shall appoint, by and with the advice and consent of the Senate, 1 individual who is a citizen of the United States, without regard to political affiliation, to the position of Executive Director of the Board for a term of 4 years.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HD80A6047765D47B09D3EEC5BFECCBF19" changed="not-changed"><enum>(2)</enum><header>Qualifications</header><text display-inline="yes-display-inline">The individual appointed as Executive Director under paragraph (1) shall be a private individual of integrity and impartiality who— </text><subparagraph commented="no" display-inline="no-display-inline" id="H5B8195C13D3E4AADBF690DDFFB7A1A26" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">is a distinguished scientist in a life sciences field; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H16B3482B13854EEAB4AC702727853630" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">is not, and has not been for the 3-year period preceding the date of the appointment—</text><clause commented="no" display-inline="no-display-inline" id="H5C11AC4D39F94713B4609B5D1A410783" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">an employee; or</text></clause><clause commented="no" display-inline="no-display-inline" id="H8E4AB792424C46EA82DCE7B09F48260D" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">a participant in high-risk life sciences research supported by Federal funding. </text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HCA320687FFD54752B4884EC4405F0B8A" changed="not-changed"><enum>(3)</enum><header>Security clearances</header><subparagraph commented="no" display-inline="no-display-inline" id="H71F98427486242FE9E078D9F33CA6C56" changed="not-changed"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">A candidate for Executive Director of the Board shall be granted all security clearances and accesses held by the Board, including to relevant Presidential and department or agency special access and compartmented access programs in an accelerated manner, subject to the standard procedures for granting such clearances. </text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H1BE4926FA4BC492F8185EE40DEEC9FF0" changed="not-changed"><enum>(B)</enum><header>Qualification prior to appointment</header><text display-inline="yes-display-inline">The President shall ensure that a candidate for Executive Director of the Board qualifies for the security clearances and accesses described in subparagraph (A) prior to appointment. </text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H6390F6023D4E4B82ABA7E12B30ACBF96" changed="not-changed"><enum>(4)</enum><header>Functions</header><text display-inline="yes-display-inline">The Executive Director of the Board shall— </text><subparagraph commented="no" display-inline="no-display-inline" id="H26ADBC0AF04F4C01A404F175E2EC7370" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">serve as principal liaison to Congress and agencies; </text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H6A86B0E83B974DE2BBB68F0CAFF07797" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">serve as chair of the Board; </text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H5B52E70BC2484C67A05685E9265367DA" changed="not-changed"><enum>(C)</enum><text display-inline="yes-display-inline">be responsible for the administration and coordination of the responsibilities of the Board; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HE8917491906B40B5BE17CA445E827D0C" changed="not-changed"><enum>(D)</enum><text display-inline="yes-display-inline">be responsible for the administration of all official activities conducted by the Board.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HED1B3E914898487AADDAAAD92425BD9B" changed="not-changed"><enum>(5)</enum><header>Removal</header><text display-inline="yes-display-inline">Notwithstanding section 7902(b)(8), the Executive Director shall not be removed for reasons other than for cause on the grounds of inefficiency, neglect of duty, malfeasance in office, physical disability, mental incapacity, or any other condition that substantially impairs the performance of the responsibilities of the Executive Director or the staff of the Board.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HFC9F468527374D2694556A72EB827DC9" changed="not-changed"><enum>(6)</enum><header>Terms</header><text>An Executive Director of the Board shall not serve more than 2 terms.</text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="HC0226DAB65314509A17B549B3FE965F4" changed="not-changed"><enum>(b)</enum><header>Staff</header><paragraph commented="no" display-inline="no-display-inline" id="H582D5984BFFA4BC8BE20061969CE9630" changed="not-changed"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Without regard to the provisions of subchapter I of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/33">chapter 33</external-xref> of title 5 governing appointments in the competitive service, the Board may appoint not more than 25 additional personnel to enable the Board and the Executive Director to perform the duties of the Board.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HF087579819394D26A290762ACBED46EE" changed="not-changed"><enum>(2)</enum><header>Qualifications</header><text display-inline="yes-display-inline">Each individual appointed to the staff of the Board—</text><subparagraph commented="no" display-inline="no-display-inline" id="HA3DBDC920FDD4A80A7DC22BFFDCD0373" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">shall be a citizen of the United States of integrity and impartiality;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H9290F82295FB48A6B2060D1EA671DD7D" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">shall have expertise in the life sciences field or the national security field; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H8AD3DBF655DB4DE0B04C68568DDB5D4D" changed="not-changed"><enum>(C)</enum><text display-inline="yes-display-inline">may not be a participant in any federally funded research activity on the date of the appointment or during the course of service of the individual on the Board. </text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HB7C2E233252B45CC8BD98E95D095B06F" changed="not-changed"><enum>(3)</enum><header>Security clearances</header><subparagraph commented="no" display-inline="no-display-inline" id="H45BDEEF733B94836B1453CD0CE084015" changed="not-changed"><enum>(A)</enum><header>In general</header><text>A candidate for appointment to the staff of the Board shall be granted all security clearances and accesses held by the Board, including to relevant Presidential and department or agency special access and compartmented access programs, in an accelerated manner, subject to the standard procedures for granting such clearances. </text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HBA7C1630A9194D2988A70D9546F9E001" changed="not-changed"><enum>(B)</enum><header>Conditional employment</header><clause commented="no" display-inline="no-display-inline" id="H322C464340BD4069B2C816F693050881" changed="not-changed"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">The Board may offer conditional employment to a candidate for a staff position of the Board pending the completion of security clearance background investigations. During the pendency of such investigations, the Board shall ensure that any such employee does not have access to, or responsibility involving, classified or otherwise restricted materials. </text></clause><clause commented="no" display-inline="no-display-inline" id="HDDBBDD781D3C489585C9AA16AEB52DAB" changed="not-changed"><enum>(ii)</enum><header>Unqualified staff</header><text display-inline="yes-display-inline">If the Board determines that an individual hired on a conditional basis under clause (i) is not eligible or otherwise does not qualify for all security clearances necessary to carry out the responsibilities of the position for which conditional employment has been offered, the Board shall immediately terminate the individual’s employment.</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H7E219564C1994DF7BB9897D3B170A267" changed="not-changed"><enum>(4)</enum><header>Support from agencies</header><subparagraph commented="no" display-inline="no-display-inline" id="H67BDE48A14CE4ED191163A94ECF31BBD" changed="not-changed"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The head of each agency shall designate not less than 1 full-time employee of the agency as the representative of the agency to—</text><clause commented="no" display-inline="no-display-inline" id="H2A36321CA56B4575AC4D06148234C744" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">provide technical assistance to the Board; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H823D4665D307419B819ECA3B5901DEC8" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">support the review process of the Board with respect to the agency under section 7906 in a non-voting staff capacity.</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HE004EF13B4004CF49C65416AB26BC290" changed="not-changed"><enum>(B)</enum><header>Prohibition</header><text display-inline="yes-display-inline">A representative of an agency designated under subparagraph (A) and any employee of an agency may not directly or indirectly influence in any capacity a determination by the Board under section 7906 with respect to life sciences research funded by the agency. </text></subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H01277AEF5BCB448FBB1A490E9D197A9D" changed="not-changed"><enum>(c)</enum><header>Compensation</header><text display-inline="yes-display-inline">Subject to such rules as may be adopted by the Board, without regard to the provisions of title 5 governing appointments in the competitive service and without regard to the provisions of chapter 51 and subchapter III of chapter 53 of that title relating to classification and General Schedule pay rates, the Executive Director of the Board shall—</text><paragraph commented="no" display-inline="no-display-inline" id="H5E3A994540894B16B1B5787EB74B4561" changed="not-changed"><enum>(1)</enum><text display-inline="yes-display-inline">be compensated at a rate not to exceed the rate of basic pay for level II of the Executive Schedule;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H864D27A36CB643C6A2B307303A82D04A" changed="not-changed"><enum>(2)</enum><text display-inline="yes-display-inline">serve the entire tenure as Executive Director as 1 full-time employee; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H30CB7A542B1F4B4F8ED67182A3E835CD" changed="not-changed"><enum>(3)</enum><text display-inline="yes-display-inline">appoint and fix the compensation of such other personnel as may be necessary to carry out this chapter.</text></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="H852218F12C5540A888A9F8BBF2E8F7EF" changed="not-changed"><enum>7904.</enum><header>Board mission and functions</header><subsection commented="no" display-inline="no-display-inline" id="HE032DEBF4EBE478EB621E14DAD7BB0DB" changed="not-changed"><enum>(a)</enum><header display-inline="yes-display-inline">Mission</header><text display-inline="yes-display-inline">The mission of the Board shall be to issue an independent determination as to whether an agency may award Federal funding for proposed high-risk life sciences research, which shall be binding upon the agency. </text></subsection><subsection commented="no" display-inline="no-display-inline" id="HEE67C9629CD04459AB887392CAADC039" changed="not-changed"><enum>(b)</enum><header>Powers</header><text display-inline="yes-display-inline">The Board shall have the authority to act in a manner to carry out the mission described in subsection (a), including authority to—</text><paragraph commented="no" display-inline="no-display-inline" id="H54388E39FDE54E7C9475DBF9E1E94560" changed="not-changed"><enum>(1)</enum><text display-inline="yes-display-inline">prescribe regulations to carry out the responsibilities of the Board;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HF0F1CD0A77044A43AD37BEFBE45AAD06" changed="not-changed"><enum>(2)</enum><text display-inline="yes-display-inline">establish a process for the review of Federal funding for high-risk life sciences research prior to the award of the Federal funding, which shall be binding upon an agency, including information designated as classified or otherwise protected from disclosure; </text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H6AA6B1825C8643CC9BBDF74E7FD5F41E" changed="not-changed"><enum>(3)</enum><text display-inline="yes-display-inline">direct an agency to make available to the Board additional information and records, including information designated as classified or otherwise protected from disclosure, that the Board determines are required to fulfill the functions and responsibilities Board under this chapter; </text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H4C37A8C25FBE4464801EA6958607C891" changed="not-changed"><enum>(4)</enum><text>review any classified research conducted or funded by any agency to determine whether the research would be considered high-risk life sciences research; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H888F8C96B6E7489D87A18D595DFEBD2C" changed="not-changed"><enum>(5)</enum><text display-inline="yes-display-inline">through the promulgation of regulations, establish processes, policies, and procedures of the Board for rendering decisions under this chapter.</text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H84B43BB87FA84D978643D31BEA74964F" changed="not-changed"><enum>(c)</enum><header>Initial requirements</header><text display-inline="yes-display-inline">The Board shall—</text><paragraph commented="no" display-inline="no-display-inline" id="H2CCE7CFBDA5D46DB83CED8F2043C7135" changed="not-changed"><enum>(1)</enum><text display-inline="yes-display-inline">not later than 180 days after the date of appointment of the initial members of the Board under section 7902, publish procedures in the Federal Register establishing the process for the review by the Board under section 7906;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H927DF248F84E4F2CB4A17E1CF8D75DC1" changed="not-changed"><enum>(2)</enum><text display-inline="yes-display-inline">prior to the establishment of the procedures under paragraph (1), consult with the appropriate congressional committees and heads of agencies for purposes of developing such procedures; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H5E0905281B884041B8D5DC52E27882B1" changed="not-changed"><enum>(3)</enum><text display-inline="yes-display-inline">not later than 270 days after the date of the enactment of this chapter, begin carrying out the duties described in section 7906.</text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H011C542E3D5C4766A07458551406C9FA" changed="not-changed"><enum>(d)</enum><header>Responsiveness to Congress</header><text>Notwithstanding any other provision of law, not later than 30 days after the date on which the Board receives a request for information from a Member of Congress, the Board shall respond to the request.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="HCC3C35F095AE4178872E61F4BE761061" changed="not-changed"><enum>(e)</enum><header>Congressional briefings</header><text>Not less frequently than quarterly, the Board shall brief the appropriate congressional committees on the work of the Board.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="HDADB64764E5F4BCF9602D3BB19C5382D" changed="not-changed"><enum>(f)</enum><header>Select agent or toxin updates</header><paragraph commented="no" display-inline="no-display-inline" id="HFB5AF4C7BE8B42CAAB6A82A8AC7EE6DB" changed="not-changed"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 15 days after the date on which the Board receives a notification that a select agent or toxin has been added to a list of agent or toxins under a regulation described in paragraph (2), the Board shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="H9853CE0035F3471587B72E0246B667FD" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">review the select agent or toxin;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HC32347BBB398414CAFC2DE55DD3966D9" changed="not-changed"><enum>(B)</enum><text>by majority vote of members of the Board, determine whether the select agent or toxin should be added into the definition of <quote>select agent or toxin</quote> under section 7901; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H5590144A28C342F1920720FAB26272BF" changed="not-changed"><enum>(C)</enum><text>publish any addition determined under subparagraph (B) in the Federal Register.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H0B4DB51FE4A547B99CAF2A69D54752C9" changed="not-changed"><enum>(2)</enum><header>Regulations described</header><text>A regulation described in this paragraph is—</text><subparagraph commented="no" display-inline="no-display-inline" id="H3F7C8C6781ED4F3FB888C7B19369DAED" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">section 73.3(b) of title 42, Code of Federal Regulations, or any successor regulation;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H7B820268D6A246059E46C56B3B53C9B6" changed="not-changed"><enum>(B)</enum><text>section 331.3(b) of title 7, Code of Federal Regulations, or any successor regulation; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H51724792B59C4B4B990826D1186EF35E" changed="not-changed"><enum>(C)</enum><text>section 121.3(b) of title 9, Code of Federal Regulations, or any successor regulation.</text></subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H07451C1E2F5E410CAD554C207ECC39D1" changed="not-changed"><enum>(g)</enum><header>Final determination authority</header><text>In any dispute with an agency or entity relating to the classification of life sciences research under this chapter, the Board shall retain final and ultimate authority in—</text><paragraph commented="no" display-inline="no-display-inline" id="HFA6E6C44DA63463C9C260D9E2D5BA825" changed="not-changed"><enum>(1)</enum><text display-inline="yes-display-inline">determining whether the life sciences research is high-risk life sciences research, dual use research of concern involving a high-consequence pathogen or gain of function research;</text></paragraph><paragraph id="H1EF6B08890344856A959D4DA1DEF8EAF" changed="not-changed"><enum>(2)</enum><text>interpreting definitions in section 7901; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H8DC9E72A0FBB4E7A8FB1BEAF779AB7C8" changed="not-changed"><enum>(3)</enum><text>determining whether a proposed Federal award for life sciences research is subject to the review process of the Board under section 7906(a)(1).</text></paragraph></subsection></section><section id="H31EABF6C5296495390E6436188B4DD9A" changed="not-changed"><enum>7905.</enum><header>Agency procedures; referral to Board</header><subsection commented="no" display-inline="no-display-inline" id="H54B605D359324F318ED1EC05A2769021" changed="not-changed"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><paragraph commented="no" display-inline="no-display-inline" id="H927CE0C4FCA447F28DA32A406669850A" changed="not-changed"><enum>(1)</enum><header>Prohibition</header><text display-inline="yes-display-inline">The head of an agency may not award Federal funding for—</text><subparagraph commented="no" display-inline="no-display-inline" id="HE1ABDC0317DD4F44849F0C3F68910922" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">high-risk life sciences research without approval by the Board under section 7906(a)(1)(B); or</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HD8097C3642BF4D9F8AF78EA55049DC6F" changed="not-changed"><enum>(B)</enum><text>life sciences research if the Board, in accordance with section 7906(a)(2)(A)(ii), submits notification to the agency under section 7906(a)(2)(B)(i) that the Board is reviewing the Federal funding for life sciences research under section 7906(a) until the date on which the Board makes a final determination with respect to the proposed Federal funding.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HD8A68D8CFD51434BA390277745F8E141" changed="not-changed"><enum>(2)</enum><header>Effective date</header><text>Paragraph (1) shall take effect on the date that is 180 days after the date of enactment of this chapter.</text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="HB179D27D9439457397AEFF84C4CECA48" changed="not-changed"><enum>(b)</enum><header>High-Risk attestation; select agent or toxin disclosure; certification</header><paragraph commented="no" display-inline="no-display-inline" id="H114D7B7340CD450998CF2CEBB0D5BD4F" changed="not-changed"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">An entity seeking Federal funding from an agency for life sciences research shall, under the penalty of perjury—</text><subparagraph id="H48D0D033A4E44DFD9E5698E55952A0F5" changed="not-changed"><enum>(A)</enum><text>attest whether—</text><clause id="HAB6B6943590B420FAB115898A9442664" changed="not-changed"><enum>(i)</enum><text>the life sciences research will constitute high-risk life sciences research; and</text></clause><clause id="HC6F438E5E07F4BEF9B94EE007A6E4237" changed="not-changed"><enum>(ii)</enum><text>the entity is performing active research with a select agent or toxin; and</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HF8418F639F4B458A911024C198DC0899" changed="not-changed"><enum>(B)</enum><text>if the entity makes a positive attestation under subparagraph (A), disclose the source of funding for all active research.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HB6C01C36AFF340B6BAF077544939FCEB" changed="not-changed"><enum>(2)</enum><header>Active research with select agents or toxins</header><subparagraph commented="no" display-inline="no-display-inline" id="H566DD82AE65D423C8772ED659C23A975" changed="not-changed"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The head of an agency that receives a disclosure from an entity under paragraph (1)(B) shall submit to the Board the disclosure.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HC2017829B936472FB0C541976870566D" changed="not-changed"><enum>(B)</enum><header>Board inquiries</header><text>The Board may contact an entity that submits a disclosure under paragraph (1)(B) to request additional information relating to the disclosure.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HF84A24566D8A45B7A7F79D0017333412" changed="not-changed"><enum>(3)</enum><header>Agency certification</header><subparagraph commented="no" display-inline="no-display-inline" id="H9D7C8EEEF93F4DAE95B2EA1EF5B76D61" changed="not-changed"><enum>(A)</enum><header>Positive attestations</header><text display-inline="yes-display-inline">The head of an agency making an award of Federal funding to an entity that makes a positive attestation under paragraph (1)(A)(i) shall—</text><clause commented="no" display-inline="no-display-inline" id="HE5718256F1944193BAEC872D18046B9E" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">submit to the Board the high-risk life sciences proposal; and</text></clause><clause commented="no" display-inline="no-display-inline" id="HC65BF8746CF24BBEAE6EA1602F2E5EAD" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">using the process established by the head of the agency under paragraph (4), certify the validity of the attestation.</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H1A0E5F91D1054D4C945B4F73C963C4DC" changed="not-changed"><enum>(B)</enum><header>Negative attestations</header><text>The head of an agency making an award of Federal funding to an entity that makes a negative attestation under paragraph (1)(A)(i) shall—</text><clause commented="no" display-inline="no-display-inline" id="HAD0ED0C1BCD94380A665E3A251C1FE5D" changed="not-changed"><enum>(i)</enum><text>review the attestation; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H8D1EC37897CB45FF83F7A0E717960D98" changed="not-changed"><enum>(ii)</enum><text>using the process established by the head of the agency under paragraph (4), certify the validity of the attestation.</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H3793BAA3A9EA4B2DACBF024E62ED5BF0" changed="not-changed"><enum>(4)</enum><header>Process for review</header><text display-inline="yes-display-inline">The head of each agency that awards Federal funding for life sciences research, in consultation with the Board, shall establish and implement a process for identifying proposals from entities seeking Federal funding for life sciences research from the agency that will constitute high-risk life sciences research.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HA9BDD2AA89AE4CC58E512C0C71422691" changed="not-changed"><enum>(5)</enum><header>Maintenance of records</header><text>The head of each agency shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="H764A1A5382CD4A3FBDFE23C06B1AE5B5" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">maintain records of the certification process described in paragraph (3) for each application for Federal funding in accordance with <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/44/31">chapter 31</external-xref> of title 44; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H2B5BB70E957B4D11A312939AEDA0428A" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">make the records maintained under subparagraph (A) available for audit and review upon request by the Board.</text></subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="HFB95E3ECB06742A0AB434558CA1E4274" changed="not-changed"><enum>(c)</enum><header>Notification</header><paragraph commented="no" display-inline="no-display-inline" id="H16486A2DE482474682D40A936B6A6CD8" changed="not-changed"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 30 days before the date on which the head of an agency plans to award Federal funding to an entity for life sciences research, the head of the agency shall submit to the Board a notification of the proposed Federal funding.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H60CB2BA7A88C47958D45C50C4EE68F48" changed="not-changed"><enum>(2)</enum><header>Contents</header><text>The notification of Federal funding for life sciences research required under paragraph (1) shall include the attestation and certification required under subsection (b).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HDEC089938E55422F8F569C2DB61B8353" changed="not-changed"><enum>(3)</enum><header>Board requests</header><subparagraph commented="no" display-inline="no-display-inline" id="H77BDD9705A374FC48008CF1A2168AF35" changed="not-changed"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The Board may request additional information from the head of an agency relating to a notification submitted under paragraph (1).</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H9DF6B80E5CD44277B0FA6D26DB9767DF" changed="not-changed"><enum>(B)</enum><header>Provision of information</header><text display-inline="yes-display-inline">The head of an agency from which the Board requests additional information under subparagraph (A) shall provide the information in a timely manner.</text></subparagraph></paragraph></subsection><subsection id="H0790F4F2CBDE4995958FD613E420E37D" changed="not-changed"><enum>(d)</enum><header>Agency procedures</header><text>Not later than 180 days after the date on which the Board publishes the process of the Board in the Federal Register pursuant to section 7904(c), the head of each agency shall publish on the website of the agency prepayment and preaward procedures of the agency with respect to Federal funding for life sciences research to—</text><paragraph commented="no" display-inline="no-display-inline" id="HB2754F9B9BFA4F9083134725FF657F5D" changed="not-changed"><enum>(1)</enum><text display-inline="yes-display-inline">guarantee that—</text><subparagraph commented="no" display-inline="no-display-inline" id="H80BA900AE05B46A7870767BFCC0F0919" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">all high-risk life science research proposals are referred to the Board before the award of Federal funding by the agency;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H2B37DF17AC054AF18D692F83202A412A" changed="not-changed"><enum>(B)</enum><text>no Federal funding for high-risk life sciences research is awarded by the agency without approval by the Board; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H369EE1C8AB094C2C84483DC392C695BD" changed="not-changed"><enum>(C)</enum><text>not later than 30 days before the date on which the head of the agency plans to award the Federal funding, the agency notifies the Board of the proposal for Federal funding; and</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HEE1E474074AA4206822E6E05B482BE07" changed="not-changed"><enum>(2)</enum><text display-inline="yes-display-inline">otherwise ensure compliance with this chapter.</text></paragraph></subsection><subsection commented="no" id="H8BB3FCFF0CF842039FCDE392D004DBF8" changed="not-changed"><enum>(e)</enum><header>Provision of additional information</header><text>Upon request by the Board, the head of an agency shall provide any information relating to Federal funding awards for life sciences research determined necessary by the Board to provide oversight of the agency.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="H703D2BDDC9094F048D2A2FDB48A9097A" changed="not-changed"><enum>(f)</enum><header>Change in circumstances during research</header><text display-inline="yes-display-inline">If, during the course of life sciences research in progress performed by an entity supported by Federal funding from an agency, circumstances arise such that the life sciences research in progress may constitute high-risk life sciences research in contravention to the attestation of the entity under subsection (b)(1)(A)(i)—</text><paragraph commented="no" display-inline="no-display-inline" id="H008BEBD04C554BB584CDC88B4187BB09" changed="not-changed"><enum>(1)</enum><text display-inline="yes-display-inline">the entity shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="H1C689337178743E896863F6D5707D3D0" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">not later than 24 hours after the identification of the change in circumstance, pause the life sciences research in progress; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H15531125F9C84C2DA319247A39DAA409" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">not later than 5 days after the date of the identification of the change in circumstance, submit to the head of the agency a written notification through an electronic or nonelectronic communication method that—</text><clause commented="no" display-inline="no-display-inline" id="H4985B397CD5A4014A2B6DEC09DAFCFC5" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">notifies the head of the agency of the possibility that the life sciences research in progress may constitute high-risk life sciences research; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H6E4F255C26DF4B5D8555A2FE62C56CFD" changed="not-changed"><enum>(ii)</enum><text>includes a detailed description of each change in circumstance that may transform the life sciences research in progress into high-risk life sciences research; and</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HEC1137DE4E4D41C18520A8F6CF2380F6" changed="not-changed"><enum>(2)</enum><text display-inline="yes-display-inline">the head of the agency shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="HF2075773E1814C6197E26900C2254082" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">using the process of the agency established under subsection (b)(4), determine whether the life sciences research in progress constitutes high-risk life sciences research;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H32CADBFEFFF34770A15FD100A2304F74" changed="not-changed"><enum>(B)</enum><text>if the head of the agency makes a negative determination under subparagraph (A), inform the entity that the entity may resume the life sciences research in progress; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HFA7B1A499E034262A468AFEF739907CE" changed="not-changed"><enum>(C)</enum><text display-inline="yes-display-inline">if the head of the agency makes a positive determination under subparagraph (A), immediately submit to the Board a notification of the Federal funding of high-risk life sciences research in progress for review under section 7906(a)(1).</text></subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H2D027AB48E9F495E9580B9A82B19BA96" changed="not-changed"><enum>(g)</enum><header>Enforcement</header><paragraph id="H11229CBE25AB439AB3495F8E154DB6F3" changed="not-changed"><enum>(1)</enum><header>Applicant requirements</header><text>If an entity seeking or receiving Federal funding from an agency knowingly fails to make a true attestation under subsection (b)(1) or promptly notify the agency of a change in circumstance in accordance with subsection (f)(1), the head of the agency shall refer the entity to the appropriate entity for suspension and debarment proceedings relating to the receipt of Federal funding.</text></paragraph><paragraph id="H29A0618782074B2CB32D121F0A0DAA7D" changed="not-changed"><enum>(2)</enum><header>Referral to inspector general</header><text>The Board shall refer any employee of an agency responsible for overseeing and reviewing research proposals relating to Federal funding that knowingly fails to comply with subsection (b)(3) to the inspector general of the agency.</text></paragraph><paragraph id="HC940DFE6D7DF4D89BC3A6D627E211099" changed="not-changed"><enum>(3)</enum><header>Employee discipline</header><subparagraph id="H67CC46A6ABAF467785B0788F5141386B" changed="not-changed"><enum>(A)</enum><header>In general</header><text>The head of an agency employing an employee who knowingly violates any provision of subsection (b)(3) (or, in the case of the head of an agency who violates any provision of subsection (b)(3), the President) shall impose on that employee—</text><clause id="HE32769BC225D46D1A4677ECCEAB80C88" changed="not-changed"><enum>(i)</enum><text>disciplinary action in accordance with <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/75">chapter 75</external-xref> of title 5 or an equivalent procedure of the agency; and</text></clause><clause id="H49495346090E431B99ABA93CE0CE154A" changed="not-changed"><enum>(ii)</enum><text>permanent revocation of any applicable security clearance held by the employee.</text></clause></subparagraph><subparagraph id="H79DCAE0D77744AD1810CEE7EF7644FBA" changed="not-changed"><enum>(B)</enum><header>Contractor penalty</header><text>In the case of contractor working under a contract with an agency who knowingly violates subsection (b)(1), the head of the agency shall refer the contractor to the appropriate entity for suspension and debarment proceedings relating to the receipt of Federal funding.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HC0D023239FD54B01AA091E6965D22D43" changed="not-changed"><enum>(C)</enum><header>Employee discipline reports</header><clause id="HA4046AA43F4E47DD9E0C8AE063B9C961" changed="not-changed"><enum>(i)</enum><header>In general</header><text>Not later than 360 days after the date of enactment of this Act, and not less frequently than once every 90 days thereafter, the head of each agency shall submit to the Board and the appropriate congressional committees a report that discloses, for the period covered by the report, each violation by an employee of the agency of subsection (b)(3).</text></clause><clause id="H01636EB6346941B3AC8CACD3C67DFA90" changed="not-changed"><enum>(ii)</enum><header>Contents</header><text>Each report submitted under clause (i) shall include, with respect to a violation described in that clause—</text><subclause id="HB10CE1C02C9C45CBA86C7819621AB515" changed="not-changed"><enum>(I)</enum><text>the name and professional title of each employee engaged in the violation;</text></subclause><subclause id="HEE0CAB79CEB2482BAF0C269AC7EC70AF" changed="not-changed"><enum>(II)</enum><text>a detailed explanation of the nature of the violation; and</text></subclause><subclause id="H50C2F9CD41804A68A609FCC6812739A6" changed="not-changed"><enum>(III)</enum><text>the date of the violation.</text></subclause></clause><clause id="HFD56CBFC642E441AAA8FC100DC137E8C" changed="not-changed"><enum>(iii)</enum><header>Publication</header><text>Not later than 5 days after the date on which the Board receives a report under clause (i), the Board shall publish on a publicly accessible and searchable website the amount of violations that have been committed under clause (i).</text></clause></subparagraph></paragraph></subsection><subsection commented="no" id="H1E06E5C28E65422E94222870B0E05F60" changed="not-changed"><enum>(h)</enum><header>Subaward and subcontractor disclosure</header><paragraph commented="no" id="HBB3F0CA5CE484958BA67B9827590FDB8" changed="not-changed"><enum>(1)</enum><header>In general</header><text>During the course of high-risk life sciences research in progress performed by an entity supported by Federal funding from an agency, the entity shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="H4B701FB4F9C0422898128A1F3977EA76" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">continuously disclose to the head of the agency any subcontracts or subawards made or planned to be made with the Federal funding; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H779C2FAA5D5B4654AAB6356C042270D9" changed="not-changed"><enum>(B)</enum><text>obtain consent from the head of the agency before awarding a subcontract or award described in subparagraph (A).</text></subparagraph></paragraph><paragraph commented="no" id="HCF06E120B63E4603A1C9BC26DEF674E9" changed="not-changed"><enum>(2)</enum><header>Agency submission</header><text>Not later than 30 days after the date on which the head of an agency receives a disclosure under paragraph (1), the head of the agency shall submit to the Board the disclosure.</text></paragraph><paragraph commented="no" id="HA48F8A297EEB48F8AB1490CD25EA8B04" changed="not-changed"><enum>(3)</enum><header>Board inquiries</header><subparagraph commented="no" id="H1A590B92B1314B62AED4BDCC1B86621D" changed="not-changed"><enum>(A)</enum><header>In general</header><text>The Board may contact an entity that submits a disclosure under paragraph (1) to request additional information relating to the disclosure.</text></subparagraph><subparagraph commented="no" id="H00C6D8FCA3FD487BB5C6CA75ED841753" changed="not-changed"><enum>(B)</enum><header>Access to reports</header><text>During the course of high-risk life sciences research in progress performed by an entity supported by Federal funding from an agency, upon request, the Board shall have access to every annual report of—</text><clause commented="no" id="H44B44BBFDF3D4F16BD7EEB485B4967C7" changed="not-changed"><enum>(i)</enum><text>the agency;</text></clause><clause commented="no" id="HC09E1BAFF66344E79E584C0586AE82C6" changed="not-changed"><enum>(ii)</enum><text>the entity performing the high-risk life sciences research; and</text></clause><clause commented="no" id="H8254647EB6904C658BC56CA3C4925D17" changed="not-changed"><enum>(iii)</enum><text>any subcontractor or subawardee of an entity described in clause (ii).</text></clause></subparagraph></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="H5A4DD8E3A0D244108AF52E665FE025B6" changed="not-changed"><enum>7906.</enum><header display-inline="yes-display-inline">Board review</header><subsection commented="no" display-inline="no-display-inline" id="H9ECCAB8B708A4E38841A9044AD35F5AC" changed="not-changed"><enum>(a)</enum><header>In general</header><paragraph commented="no" display-inline="no-display-inline" id="HB278445754BF439EBC5F08A70080F5C2" changed="not-changed"><enum>(1)</enum><header>High-risk life sciences research</header><text display-inline="yes-display-inline">Not later than 120 days after the date on which the Board receives a notification from an agency under section 7905(c) relating to proposed Federal funding for life sciences research that constitutes high-risk life sciences research or the Board receives a notification from an agency under section 7905(f)(2)(C) relating to Federal funding of research in progress that constitutes high-risk life sciences research, the Board shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="H38C43560864543F8ACD5A8A21240A824" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">review the proposed Federal funding or high-risk life sciences research in progress;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H51D944353C804158A5F754A22BA7B80D" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">by a majority vote, determine whether the agency may award the proposed Federal funding or continue to award the Federal funding for the high-risk life sciences research in progress; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H7765EFAD278B49A1A7A45242457E0907" changed="not-changed"><enum>(C)</enum><text>by a majority vote, determine with respect to the high-risk life sciences research funded by the proposed Federal funding or Federal funding for high-risk life sciences research in progress—</text><clause commented="no" display-inline="no-display-inline" id="H4732D34A74DA4DD3993CBEADD523C839" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">the minimum required biosafety containment level, engineering controls, and operational controls;</text></clause><clause commented="no" display-inline="no-display-inline" id="HEDD99363459D4E7387502374579D99CA" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">the minimum required biosecurity engineering controls and operational controls; and</text></clause><clause commented="no" display-inline="no-display-inline" id="HDBD974295DE640E2B45ADA410A64FFAA" changed="not-changed"><enum>(iii)</enum><text>the minimum required personnel assurance controls.</text></clause></subparagraph></paragraph><paragraph id="HF016FA5537B24821903868E2C17BAF40" changed="not-changed"><enum>(2)</enum><header>Proposed life sciences research</header><subparagraph commented="no" display-inline="no-display-inline" id="HF8DB111C94F14043B2EBB1E835BBE9E2" changed="not-changed"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">With respect to proposed Federal funding by an agency for life sciences research, the Board may—</text><clause commented="no" display-inline="no-display-inline" id="H26C389716E35475DB1B79BAA81CA3501" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">review the proposed Federal funding; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H2836AAD043B34E74ADF7B5FC9B9D4843" changed="not-changed"><enum>(ii)</enum><text>determine whether the Board should review the proposed Federal funding in accordance with paragraph (1).</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H1B8E800D9CC141D7850E15B811355067" changed="not-changed"><enum>(B)</enum><header>Notification</header><text>If the Board makes a positive determination under subparagraph (A)(ii) with respect to proposed Federal funding by an agency—</text><clause commented="no" display-inline="no-display-inline" id="H7754B7905E3C4AF99BEA6AB465E3A8DB" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">the Board shall notify the head of the agency; and</text></clause><clause commented="no" display-inline="no-display-inline" id="HCE3490DC943746BEA11C7C4A340A2F1D" changed="not-changed"><enum>(ii)</enum><text>the head of the agency may not award the proposed Federal funding until the date on which the Board makes a final determination with respect to the proposed Federal funding under paragraph (1).</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HF39648B1D6B449C3A02B609B9C015CE0" changed="not-changed"><enum>(3)</enum><header>Past funding</header><text>With respect to life sciences research performed with Federal funding awarded by an agency before the date of enactment of this chapter, the Board may review and audit the research in order to assess the compliance of the agency with the provisions of this chapter.</text></paragraph><paragraph id="H0A909F21EE144E5D9AA9FACA0CB5A19B" changed="not-changed"><enum>(4)</enum><header>Ongoing funding for life sciences research</header><text>With respect to Federal funding for life sciences research in progress awarded by an agency before the date of enactment of this Act that the Board determines may constitute high-risk life sciences research, the Board may—</text><subparagraph commented="no" display-inline="no-display-inline" id="H7463B82EA51C428AB571158011B12BCB" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">direct the agency to temporarily suspend the Federal funding;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H75683708721341C69D58E92AEFF07C93" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">require the agency to provide complete information on the Federal funding in order for the Board to complete a review of the life sciences research under paragraph (1); and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H361F6B320F7B45CAA3DEAD87D344EFDF" changed="not-changed"><enum>(C)</enum><text display-inline="yes-display-inline">by a majority vote of members of the Board, determine whether the agency may continue the Federal funding.</text></subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H96D1E87A93B248EE99EC34460408F7AE" changed="not-changed"><enum>(b)</enum><header>Considerations</header><paragraph commented="no" display-inline="no-display-inline" id="HD801987B284F45DC821E0C59D6CCDE9C" changed="not-changed"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">In making a determination under subsection (a)(1)(B), the Board shall consider, with respect to the high-risk life sciences research that will be conducted with the proposed Federal funding or high-risk life sciences research in progress—</text><subparagraph commented="no" display-inline="no-display-inline" id="H22A292F3115649439F26AA9B00528CF2" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">whether the research poses a threat to public health;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HAB1AE85690F04235A71A4945B3C6B990" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">whether the research poses a threat to public safety;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HCF5AA468377D41AEB0BF361415A1BDAE" changed="not-changed"><enum>(C)</enum><text>whether the research has a high probability of producing benefits for public health;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HE5C589B4632F463ABF35E0475A6FE391" changed="not-changed"><enum>(D)</enum><text>whether the research poses a threat to large populations of animals and plants;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H80D4147008BC40FEADB8BA2285267CBD" changed="not-changed"><enum>(E)</enum><text display-inline="yes-display-inline">whether the research poses a threat to national security;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H1872100419E54177B741FE84647818E7" changed="not-changed"><enum>(F)</enum><text display-inline="yes-display-inline">whether the research is proposed to be conducted in whole or at least in part in a foreign country; </text></subparagraph><subparagraph id="H13E3FF56EB044C61AE9F1808DA1C08C1" changed="not-changed"><enum>(G)</enum><text>the reasonably anticipated material risks of the research;</text></subparagraph><subparagraph id="HF2009EB7E19B4FB98A9ECF6BF03DE743" changed="not-changed"><enum>(H)</enum><text>the reasonably anticipated information risks of the research;</text></subparagraph><subparagraph id="H44613648C09B4926BD71A14BC24CE14F" changed="not-changed"><enum>(I)</enum><text>the reasonably anticipated benefits of the research;</text></subparagraph><subparagraph id="HE9BB27FFE4A94B03B8DB0A316771B933" changed="not-changed"><enum>(J)</enum><text>whether the reasonably anticipated benefits of the research outweigh the reasonably anticipated risks; and</text></subparagraph><subparagraph id="H1396F7B999A747739A2F1DE47D331971" changed="not-changed"><enum>(K)</enum><text>whether the benefits of the research could be obtained through procedures posing lower risks. </text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H7209F7D5D77F447F981330304C5FCAED" changed="not-changed"><enum>(2)</enum><header>Weight of factors</header><text>The presence or absence of any factor under paragraph (1) shall not be decisive with respect to the determination of the Board under subsection (a)(1)(B).</text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H3433ECE79C59468D859BE87349DB8CDB" changed="not-changed"><enum>(c)</enum><header>Notice following review and determination</header><paragraph commented="no" display-inline="no-display-inline" id="H4C71ACB398E64EEA8BCCDCB369F426EE" changed="not-changed"><enum>(1)</enum><header>Agency notification</header><text display-inline="yes-display-inline">Not later than 5 days after the date on which the Board makes a determination under subsection (a)(1)(B) with respect to Federal funding by an agency, the Executive Director of the Board shall notify the head of the agency of the determination.</text></paragraph><paragraph commented="no" id="H88ED01C9FC054FDEBDAC5B7518B4DD03" changed="not-changed"><enum>(2)</enum><header>Board consultation</header><subparagraph commented="no" id="H1B05335968F344659DF807D5029A7F00" changed="not-changed"><enum>(A)</enum><header>In general</header><text>Not later than 10 days after receiving a notification from the Board under paragraph (1), the head of an agency may request a meeting with the Board to discuss the determination of the Board.</text></subparagraph><subparagraph commented="no" id="H44AB0681CAC349E5B28E8617EF3E5B88" changed="not-changed"><enum>(B)</enum><header>Board response</header><text>The Board shall schedule a meeting requested by the head of an agency under subparagraph (A) in a timely manner.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H30EA90D8650541E5A52BE0B192CA6015" changed="not-changed"><enum>(3)</enum><header>Notification to appropriate congressional committees</header><text display-inline="yes-display-inline">If the Board determines that the head of an agency may not proceed with an award of proposed Federal funding under this section, the Executive Director of the Board shall notify the appropriate congressional committees when the Board notifies the head of the agency. </text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="HA372758892504DEFA74AD55247F8C077" changed="not-changed"><enum>(d)</enum><header>Request for expedited review</header><paragraph commented="no" display-inline="no-display-inline" id="H2EC523F3689E41D9A83294B056E72CF4" changed="not-changed"><enum>(1)</enum><header display-inline="yes-display-inline">Definition</header><text>In this subsection, the term <term>emergency research</term> means high-risk life sciences research submitted to the Board that relates to a public health emergency or addresses a specific national security concern.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HB5894C6FA1EA4769AED6AC35A73919B0" changed="not-changed"><enum>(2)</enum><header>Request; notification</header><text>The head of an agency seeking expedited review from the Board to award Federal funding for emergency research shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="HADD887C758734B509D9F8D9BE0DF6803" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">include a request for expedited review in the notification required under section 7905(c); and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HEBF130EC078B4DCFACFFB1872A76F339" changed="not-changed"><enum>(B)</enum><text>on the date of the notification described in subparagraph (A), submit to the Board and the appropriate congressional committees a notification that explains why the specific public health emergency or national security concern necessitates expedited review under this subsection.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H5D1C2B808D7249BBB092A7C8D7F0C979" changed="not-changed"><enum>(3)</enum><header>Internal process</header><text>The Board shall establish an internal process under which the Board will give proposed emergency research expedited review under this section.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HBEF47431626249F0AE133A96A0D4641B" changed="not-changed"><enum>(4)</enum><header>Temporary emergency research</header><text display-inline="yes-display-inline">If the Board does not notify the head of an agency with a determination under subsection (a)(1)(B) with respect to proposed emergency research by the date that is 15 days after the date on which the head of the agency submits a request under paragraph (2)(A), the head of the agency may award Federal funding for the emergency research on a temporary basis.</text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H30F25E3B248A4FDCA4794DDDDD4D7227" changed="not-changed"><enum>(e)</enum><header>Scientific expert panels</header><paragraph commented="no" display-inline="no-display-inline" id="H666D3A8F0B5C42688E77FD2105471103" changed="not-changed"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Board may establish a scientific panel of nongovernmental experts to advise the Board in the review by the Board of life sciences research pursuant to this chapter.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H6289015E9CC54022ABCA923E6239B4C8" changed="not-changed"><enum>(2)</enum><header>Policies and procedures</header><text display-inline="yes-display-inline">The Board shall establish and publish in the Federal Register procedures and policies relating to conflicts of interest, recusal, expertise, and related matters before the establishment of the panel described in paragraph (1).</text></paragraph><paragraph id="H0D7859875A584DD8886CAD087CA28433" changed="not-changed"><enum>(3)</enum><header>Prohibition</header><text>An individual serving on the panel established under paragraph (1) may not advise the Board on any matter with respect to which the individuals has an identified or perceived conflict of interest.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HF4248D43582640989C143F06777A1DB7" changed="not-changed"><enum>(4)</enum><header>Report</header><subparagraph commented="no" display-inline="no-display-inline" id="HABC084D5BDF24DDFBF7C6F8E553A7AFA" changed="not-changed"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 30 days after the date on which the Board establishes a panel established under paragraph (1), the Board shall submit to the appropriate congressional committees a report that includes the names, qualifications, and any identified or perceived conflicts of interest of individuals who serve on the panel.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HAC41B31970074EF1A7A5B700C8F5B189" changed="not-changed"><enum>(B)</enum><header>Panel changes</header><text>Upon a change of personnel on the panel established under paragraph (1), the Board shall immediately submit to the appropriate congressional committees an update to the report required under subparagraph (A).</text></subparagraph></paragraph></subsection><subsection id="HD438AB9446004166B763BF9FF8A0023B" changed="not-changed"><enum>(f)</enum><header>Report</header><paragraph commented="no" display-inline="no-display-inline" id="HE790065DDA094FCE90A6AFA305335CAF" changed="not-changed"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 360 days after the date on which the Board establishes the panel described in subsection (e)(1), and annually thereafter, the Board shall submit to the appropriate congressional committees a report, which shall include a classified annex, summarizing, with respect to each determination by the Board under this section relating to high-risk life sciences research—</text><subparagraph commented="no" display-inline="no-display-inline" id="H530FB06A5EC245B4BB33B9EE1C2F4494" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">the findings of the Board;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HA0A420A09B1C464A83DCC8429BE4B7BD" changed="not-changed"><enum>(B)</enum><text>the determination of the Board;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HA75FBEEC8969423488F08AAFB17E6F27" changed="not-changed"><enum>(C)</enum><text>the name and location of the entity proposing the life sciences research;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H5D70067827724A109973B9983DD14AA1" changed="not-changed"><enum>(D)</enum><text>the name and location of any recipient of a subaward or subcontractor of an entity proposing life sciences research and the nature of the participation of such a recipient or subcontractor; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H5E01A0B567E94EF9BF6C6868A0C2862B" changed="not-changed"><enum>(E)</enum><text>an account of significant challenges or problems, including procedural or substantive challenges or problems, that arise during the course of the work of the Board, including the views of any member of the Board who wishes to have those views included in the report.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H649F6AC753BA49189561B053C213A4ED" changed="not-changed"><enum>(2)</enum><header>Public report</header><text>On the date on which the Board submits a report required under paragraph (1), the Board shall make the report, other than the classified annex included in the report, available on a website.</text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H4F9134D422294289B6395DD5EDB9C64F" changed="not-changed"><enum>(g)</enum><header>Effective date</header><text>This section shall take effect on the date that is 270 days after the date of enactment of this chapter.</text></subsection></section><section commented="no" display-inline="no-display-inline" id="H0773999330DD4FE885DF581E00ECF7F6" changed="not-changed"><enum>7907.</enum><header>GAO Audits</header><text display-inline="no-display-inline">The Comptroller General of the United States shall periodically audit the Board.</text></section><section commented="no" display-inline="no-display-inline" id="H6B988031E0A8414991DB2216B0A0E915" changed="not-changed"><enum>7908.</enum><header>Funding</header><text display-inline="no-display-inline">There is authorized to be appropriated to the Board to carry out this chapter $30,000,000 for each of fiscal years 2026 through 2035.</text></section></chapter><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection commented="no" display-inline="no-display-inline" id="HDAE8E1524DC74147B8E3F578A901E4C7" changed="not-changed"><enum>(b)</enum><header>Clerical amendment</header><text>The table of chapters for subtitle V of title 31, United States Code, is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HEBFC65B8DF5C46EBAE6872E81199289B" changed="not-changed"><toc changed="not-changed"><multi-column-toc-entry bold="off" level="section" changed="not-changed"><toc-enum>79. </toc-enum><level-header level="section">Life Sciences Research Security Board</level-header><target>7901</target></multi-column-toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection commented="no" display-inline="no-display-inline" id="H95FEF9F224E6424892915B890A3F63A1" changed="not-changed"><enum>(c)</enum><header>Financial disclosure reports of Board members</header><text>Section 13103(f) of title 5, United States Code, is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="H4D13D4F6FD7E49B9BD780151832B28D9" changed="not-changed"><enum>(1)</enum><text>in paragraph (11), by striking <quote>and</quote> at the end;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HF4BAEE70A1B14E1F9ABFB720BCD87B29" changed="not-changed"><enum>(2)</enum><text>in paragraph (12), by striking the period at the end and inserting <quote>; and</quote>; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H3C52A2B307C34DE7967C464308DBF238" changed="not-changed"><enum>(3)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HF27BBA9FEC534136B228DC7FE2C9AA9F" changed="not-changed"><paragraph id="H736919FED48F4F94980AE205C9637604" changed="not-changed"><enum>(13)</enum><text>a member of the Life Sciences Research Security Board established under section 7902 of title 31.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section></legis-body></bill> 

